Karyopharm Therapeutics Inc.
) shares almost doubled (up 93.51%) on encouraging initial data
from a phase I study on its oncology candidate, selinexor, for
patients suffering from multiple myeloma. The new data was also
presented at the European Hematology Association (EHA). Selinexor
is a first-in-class oral selective inhibitor of nuclear export
Eight relapsed and/or refractory multiple myeloma patients were
treated with either selinexor (45 mg/m² twice weekly) alone or
selinexor in combination with low-dose dexamethasone (20 mg twice
weekly) as a part of the phase I study in patients with advanced
hematological malignancies. Clinical benefit response rate of 75%
and overall response rate of 50% were observed in the study.
Among these eight patients, the best responses were one stringent
complete response, three partial responses, two minor responses,
one with progressive disease while one was non-evaluable.
Selinexor Development Status
Currently, Karyopharm is enrolling patients in three ongoing phase
I studies on selinexor in advanced hematologic malignancies, solid
tumors and sarcomas. In all the studies, patients whose disease has
relapsed and/or refractory to all available classes of approved
therapies and is progressing will be enrolled. 12 additional
multiple myeloma patients may be dosed with a selinexor and
dexamethasone combination as a part of the ongoing phase I
Karyopharm has also initiated phase II studies to evaluate
selinexor in patients with metastatic hormone-refractory prostate
cancer, relapsed glioblastoma multiforme and in cervical, ovarian
and uterine carcinomas. In 2014, Karyopharm plans to initiate
additional studies in squamous head, neck or lung cancer, Richter's
syndrome and diffuse large B-cell lymphoma among other indications.
We expect investor focus to remain on updates pertaining to
Karyopharm carries a Zacks Rank #3 (Hold). Some better-ranked
stocks in the health care sector include
Gilead Sciences Inc.
Alexion Pharmaceuticals, Inc.
). While Gilead and Allergan are Zacks Rank #1 (Strong Buy) stocks,
Alexion holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ALEXION PHARMA (ALXN): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
KARYOPHARM THER (KPTI): Free Stock Analysis
To read this article on Zacks.com click here.